ArticleGastroenterology & hepatology2011
Antibiotics for the treatment of irritable bowel syndrome.
Article in Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.Digestive diseases and sciences · 2017Trial
- Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3.Asian journal of andrologyTrial
- Impact of cefixime and probiotics on functional abdominal bloating: a pilot study.Przeglad gastroenterologiczny · 2024Article
- Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review.World journal of clinical cases · 2023Review
- The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders.Microorganisms · 2023Article
- Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review.Gut microbiome (Cambridge, England) · 2022Review
- Clinical Management of the Microbiome in Irritable Bowel Syndrome.Journal of the Canadian Association of Gastroenterology · 2021Article
- The characteristics of intestinal flora of IBS-D with different syndromes.Immunity, inflammation and disease · 2020Article
- Article
- Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- The role of a sequencing-based clinical intestinal screening test in patients at high-risk for Clostridium difficile and other pathogens: a case report.Journal of medical case reports · 2019Article
- Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome.Gastroenterology research and practice · 2019Review
- Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats.Microbiome · 2018Article
- Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.Clinical and experimental gastroenterology · 2018Review
- MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats.Oncotarget · 2017Article
- Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.Journal of neurogastroenterology and motility · 2017Review
- Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer.Molecular and clinical oncology · 2016Article
- The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.Advanced biomedical research · 2016Article
- Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Pharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with an estimated worldwide prevalence of 10-20%. IBS can be associated with severe gastrointestinal symptoms, including abdominal pain, bloating, and altered bowel function. Although the causes of IBS remain undefined, recent research has increasingly suggested roles for gut flora in IBS. These roles involve postinfectious IBS, which can occur after a single episode of acute gastroenteritis, and small intestinal bacterial overgrowth, in which elevated populations of aerobic and anaerobic bacteria cause abdominal pain and altered bowel function. More recently, potential roles for methanogens in contributing to IBS subtypes have also been identified. In this paper, we review the different mechanisms by which gut flora may contribute to IBS and also discuss the efficacy and safety of various antibiotic therapies for treating IBS symptoms.
Indexed as
Identifiers
22298980PMC3264894W85378937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.